Green Cross Medical Science Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

Is Green Cross Medical Science (KOSDAQ:142280) A Risky Investment?

Aug 30

There's No Escaping Green Cross Medical Science Corporation's (KOSDAQ:142280) Muted Revenues Despite A 45% Share Price Rise

Aug 08

We Think Green Cross Medical Science's (KOSDAQ:142280) Solid Earnings Are Understated

Mar 26

Investors Shouldn't Be Too Comfortable With Green Cross Medical Science's (KOSDAQ:142280) Robust Earnings

Mar 23

These 4 Measures Indicate That Green Cross Medical Science (KOSDAQ:142280) Is Using Debt Extensively

Feb 24

Is Green Cross Medical Science's (KOSDAQ:142280) Share Price Gain Of 128% Well Earned?

Jan 28

Is Green Cross Medical Science Corporation (KOSDAQ:142280) Popular Amongst Insiders?

Jan 02

Should We Be Excited About The Trends Of Returns At Green Cross Medical Science (KOSDAQ:142280)?

Dec 07

CEO

Green Cross Medical Science heeft geen CEO, of we hebben geen gegevens over hen.

Green Cross Medical Science Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Green Cross Medical Science Corporation, Annual General Meeting, Mar 24, 2021

Recent updates

New minor risk - Shareholder dilution

Is Green Cross Medical Science (KOSDAQ:142280) A Risky Investment?

Investor sentiment deteriorates as stock falls 19%

New major risk - Financial position

There's No Escaping Green Cross Medical Science Corporation's (KOSDAQ:142280) Muted Revenues Despite A 45% Share Price Rise

New minor risk - Share price stability

We Think Green Cross Medical Science's (KOSDAQ:142280) Solid Earnings Are Understated

Full year 2023 earnings released: EPS: ₩85.00 (vs ₩170 loss in FY 2022)

New minor risk - Share price stability

Full year 2022 earnings released: ₩170 loss per share (vs ₩1,006 loss in FY 2021)

Green Cross Medical Science Corporation announced that it has received KRW 30 billion in funding from Daishin Securities Co. Ltd., Investment Arm and other investors

Investor sentiment improved over the past week

Green Cross Medical Science Corporation announced that it expects to receive KRW 30 billion in funding from Daishin Securities Co. Ltd., Investment Arm, and other investors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investors Shouldn't Be Too Comfortable With Green Cross Medical Science's (KOSDAQ:142280) Robust Earnings

Full year 2020 earnings released: EPS ₩311 (vs ₩1,017 loss in FY 2019)

New 90-day low: ₩10,800

These 4 Measures Indicate That Green Cross Medical Science (KOSDAQ:142280) Is Using Debt Extensively

Oxford Immunotec Global PLC Enters into A Memorandum of Understanding Green Cross Medical Science Corp. to Market the T-SPOT Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea

Green Cross Medical Science Corporation, Annual General Meeting, Mar 24, 2021

New 90-day low: ₩13,350

Is Green Cross Medical Science's (KOSDAQ:142280) Share Price Gain Of 128% Well Earned?

New 90-day low: ₩13,750

Is Green Cross Medical Science Corporation (KOSDAQ:142280) Popular Amongst Insiders?

New 90-day low: ₩13,900

Should We Be Excited About The Trends Of Returns At Green Cross Medical Science (KOSDAQ:142280)?

New 90-day high - ₩13,450

New 90-day high - ₩12,300

CEO